Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New Non-Hormonal pill eases menopause hot flashes in german women

NCT ID NCT07455812

Symptom relief Sponsor: Astellas Pharma Europe Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 11, 2026 · Updated 2 times

Summary

This study looks at how well fezolinetant, a non-hormonal tablet, helps reduce hot flashes and night sweats in menopausal women in Germany. About 105 women whose doctor already prescribed fezolinetant will take the tablet and complete virtual surveys over 6 months. The goal is to see if women feel their symptoms improve in real-life settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

105 people

The number who actually took part.

Started

Oct 2024

Finished

Jul 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants who are prescribed fezolinetant for the treatment of VMS associated with menopause in a real-world setting as part of routine clinical care.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participant has been prescribed fezolinetant for the treatment of VMS associated with menopause according to routine clinical practice * Participant is living in Germany * Participant is able to communicate in German language * Participant is able to use digital tools and have access to an internet-capable device Exclusion Criteria: * A patient will be excluded if she is participating in clinical trials.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hot flashes are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Hot Flashes

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hot flashes

Contacts and locations

Locations

  • Site DE49001

    Berlin, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.